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Body mass index and psychiatric 
disorders: a Mendelian 
randomization study
Fernando Pires Hartwig1, Jack Bowden2,3, Christian Loret de Mola1, Luciana Tovo-Rodrigues1, 
George Davey Smith2 & Bernardo Lessa Horta1
Obesity is a highly prevalent risk factor for cardiometabolic diseases. Observational studies suggest 
that obesity is associated with psychiatric traits, but causal inference from such studies has several 
limitations. We used two-sample Mendelian randomization methods (inverse variance weighting, 
weighted median and MR-Egger regression) to evaluate the association of body mass index (BMI) 
with three psychiatric traits using data from the Genetic Investigation of Anthropometric Traits and 
Psychiatric Genomics consortia. Causal odds ratio estimates per 1-standard deviation increment in BMI 
ranged from 0.88 (95% CI: 0.62; 1.25) to 1.23 (95% CI: 0.65; 2.31) for bipolar disorder; 0.93 (0.78; 1.11) 
to 1.41 (0.87; 2.27) for schizophrenia; and 1.15 (95% CI: 0.92; 1.44) to 1.40 (95% CI: 1.03; 1.90) for major 
depressive disorder. Analyses removing potentially influential SNPs suggested that the effect estimates 
for depression might be underestimated. Our findings do not support the notion that higher BMI 
increases risk of bipolar disorder and schizophrenia. Although the point estimates for depression were 
consistent in all sensitivity analyses, the overall statistical evidence was weak. However, the fact that 
SNP-depression associations were estimated in relatively small samples reduced power to detect causal 
effects. This should be re-addressed when SNP-depression associations from larger studies become 
available.
Obesity is a major public health concern with well-established risk-increasing effects on cardiometabolic dis-
eases1. Given its high prevalence worldwide1, investigating if obesity influences additional diseases is relevant for 
understanding the range of its health consequences.
Psychiatric disorders are one of the main causes of years lived with disability globally2. There is considerable 
evidence suggesting an association between obesity and psychiatric disorders, including depression3,4, bipolar 
disorder5,6 and schizophrenia7,8. Reverse causality could be one of the explanations for this association because 
increase in body weight is a side effects of some anti-psychotic medications6,9. Besides treatment, biological, 
psychological, and sociodemographic variables related to psychiatric disorders may affect lifestyle factors such as 
physical activity and diet and thus lead to obesity10,11.
Cohort studies provide support that obesity both predicts and can be predicted by depression3,12,13 and 
bipolar disorder14. Moreover, higher frequencies of obesity measures were reported in first episode and/or 
medication-naive schizophrenia patients15,16, although not universally17,18. A recent instrumental variable analysis 
supported the hypothesis that obesity influences depression19.
Most of the evidence regarding the association of obesity with psychiatric disorders comes from observational 
studies, which present several limitations for causal inference, including residual confounding, measurement 
error and reverse causation20,21. Using genetic variants as instrumental variables for modifiable disease risk fac-
tors or exposures (ie, Mendelian randomization) contributes to overcome such limitations given Mendel’s laws, 
the fact that germline genetic variants are determined at conception and the general lack of association between 
genetic variants and common confounders of observational associations21–23.
Mendelian randomization relies on assuming that any association between the genetic instrument(s) and the 
health outcome is entirely mediated by the exposure (ie, vertical pleiotropy)21–23. However, the polygenic nature 
of complex traits increases the probability of existing biological links between exposure-associated variants and 
the outcome not mediated by the exposure itself (ie, horizontal pleiotropy). Indeed, the largest genome-wide 
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association study (GWAS) of body mass index (BMI) to date identified variants implicated in biological pathways 
related to the central nervous system24, thus potentially complicating Mendelian randomization involving BMI 
and psychiatric disorders.
Previous Mendelian studies on this topic yielded inconsistent findings. However, such studies have some lim-
itations, including using only FTO and MC4R variants as genetic instruments25,26, both of which are pleiotropic 
loci27,28 that possibly violate Mendelian randomization assumptions25,29,30. Another limitation is that the studies 
were performed in the single-sample context25,26,29,31,32, which renders the results prone to bias towards the obser-
vational (and possibly confounded) estimate if the genetic instrument is weakly associated with BMI33,34.
Currently, many GWAS consortia make summary-level results freely available. Such data can be used to obtain 
causal effect estimates based on multiple single nucleotide polymorphisms (SNPs) using the inverse-variance 
weighting (IVW) method35. This is likely to improve statistical power because SNP-exposure and SNP-outcome 
associations are typically estimated in large samples. Moreover, the recently proposed MR-Egger regression36 and 
weighted median37 methods can be used in summary data Mendelian randomization investigations as sensitivity 
analyses to detect and (at least partially) account for violations of instrumental variable assumptions. MR-Egger 
causal effect estimates are consistent even if all instruments are invalid, as long as SNP-exposure and direct (ie, 
not solely mediated by the exposure) SNP-outcome associations are independent. The weighted median requires 
that at least 50% of the information come from valid instruments; if this is satisfied, its causal effect estimate is 
consistent regardless of the type of horizontal pleiotropy in the invalid instruments (see Materials and Methods 
section for details). We aimed at estimating the causal effect of BMI on three psychiatric traits using these three 
Mendelian randomization methods in a two-sample framework.
Results
Estimation of causal effects of BMI on schizophrenia using Mendelian randomization. A 
flowchart depicting the selection process of the genetic variants used in Mendelian randomization analysis is 
shown in Fig. 1. Table 1 describes each psychiatric dataset. SNP-BMI F-statistics in the Genetic Investigation of 
Anthropometric Traits (GIANT) consortium dataset were similar across the variants available in each psychiatric 
dataset, with mean and median values about 56 and 34, respectively. However, approximate SNP-BMI F-statistics 
(ie, instrument strength) in psychiatric datasets were considerably different: mean and median values were ~3 
and ~2, respectively, for bipolar and major depressive disorders, and 14.4 and 9.0 for schizophrenia. Tetrachoric 
correlations between GIANT and each PGC datasets were very close to zero, suggesting that there was, at most, 
little sample overlap (see Materials and Methods for details).
Mendelian randomization results for each psychiatric disorder are shown in Table 2. For bipolar disorder, 
odds ratio of 0.90 (95% CI: 0.69; 1.16) and 0.88 (95% CI: 0.62; 1.25) per 1-standard deviation (SD) increment in 
BMI were obtained using the IVW and weighted median methods. These estimates were directionally inconsist-
ent with regular and Simulation Extrapolation (SIMEX)-corrected MR-Egger estimates of 1.23 (95% CI: 0.65; 
2.31) and 1.26 (95% CI: 0.63; 2.52), respectively. Schizophrenia presented a similar pattern, with IVW and 
weighted median odds ratio of 0.98 (0.80; 1.19) and 0.93 (0.78; 1.11), respectively, while regular and 
SIMEX-corrected MR-Egger estimates were 1.41 (0.87; 2.27) and 1.46 (0.86; 2.47), respectively. Regarding major 
depressive disorder, all methods yielded directionally consistent estimates: IVW, weighted median, regular and 
SIMEX-corrected MR regression odds ratio were (respectively) 1.15 (95% CI: 0.92; 1.44), 1.40 (95% CI: 1.03; 
1.90), 1.28 (95% CI: 0.74; 2.24) and 1.33 (95% CI: 0.72; 2.47). IGX
2  (which measures regression dilution bias in 
MR-Egger regression)38 was 88.6%, 88.2% and 87.9% for bipolar disorder, major depressive disorder and schizo-
phrenia, respectively, suggesting an attenuation of the causal effect estimates of about 12% due to regression 
dilution bias (which can be seen comparing regular and SIMEX-corrected MR-Egger results). All MR-Egger 
intercepts were close to 1.00 and none achieved conventional statistical significance levels, suggesting that there 
was no strong directional horizontal pleiotropy under the InSIDE assumption.
Figure 1. Flowchart depicting the selection process of the genetic instruments for body mass index. BMI: 
Body mass index. SNP: Single nucleotide polymorphism. GIANT: Genetic Investigation of Anthropometric 
Traits consortium. PGC: Psychiatric Genomics Consortium.
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Sensitivity analyses removing influential instruments and within subgroups of biological cat-
egories. SNPs were classified as influential using statistical tests based on studentized residuals and Cook’s 
distance (see Materials and Methods for details). The following SNPs – rs number (gene locus) – were classified 
as influential: rs4256980 (TRIM66), rs12401738 (FUBP1), rs9925964 (KAT8), rs11191560 (NT5C2), rs11057405 
(CLIP1) in bipolar disorder; rs13107325 (SLC39A8), rs11191560 (NT5C2), rs9400239 (FOXO3) and rs4787491 
(INO80E) in schizophrenia; and rs571312 (MC4R), rs1462433 (HNF4G), rs6785875 (FHIT) and rs11191560 
(NT5C2) in major depressive disorder (Fig. 2). Removing influential SNPs made virtually no difference in bipo-
lar disorder results. Regarding schizophrenia, removing influential SNPs attenuated (and increased precision) 
regular and SIMEX-corrected (respectively) MR-Egger regression odds ratio to 1.22 (95% CI: 0.83; 1.81) and 
1.25 (95% CI: 0.81; 1.92) per 1-SD increment in BMI. The magnitude of all major depressive disorder estimates 
increased, ranging from 1.25 (95% CI: 1.02; 1.52) to 1.60 (95% CI: 0.93; 2.75) using IVW and SIMEX-correct 
MR-Egger, respectively.
When dividing SNPs into neuronal-related vs. non-neuronal-related subgroups, the results were generally 
similar between subgroups (Table 3). Regarding bipolar disorder, in all cases the IVW and weighted median 
estimates were directionally inconsistent with MR-Egger results. Regular and SIMXEX-corrected MR-Egger odds 
ratio estimates were weaker in the neuronal-related (1.19 [95% CI: 0.54; 2.60] and 1.19 [0.51; 2.75] per 1-SD 
increment in BMI, respectively) than in the remaining SNPs (1.33 [95% CI: 0.38; 4.68] and 1.42 [95% CI: 0.32; 
6.34], respectively). This difference was more evident after excluding influential SNPs, but in both cases confi-
dence intervals of one subgroup largely included the point estimate of the other subgroup. In schizophrenia, the 
odds ratio estimates were also inconsistent, especially in the non-neuronal subgroup. Again, MR-Egger estimates 
were stronger in the non-neuronal subgroup, although such difference was attenuated after excluding influential 
SNPs and confidence intervals were wide. All major depressive disorder estimates were directionally consistent 
and similar between neuronal-related and non-neuronal subgroups. Excluding influential SNPs increased the 
estimates (especially IVW and MR-Egger ones).
IVW estimates for each outcome when SNPs belonging to a given biological category were removed are shown 
in Table 4. Regarding bipolar disorder, all but one of the IVW odds ratio estimates were directionally consistent, 
ranging from 0.75 (95% CI: 0.55; 1.03) to 0.98 (95% CI: 0.75; 1.28) per 1-SD increment in BMI. The exception 
was an estimate of 1.06 (95% CI: 0.81; 1.41), obtained after excluding SNPs prioritized by annotation tools, but 
that do not belong to a well-defined biological category (referred to as an “unspecified” biological category). 
Schizophrenia estimates were more heterogeneous, with 10 being smaller than 1 (ranging from 0.92 to 0.99) and 
six being larger than or equal to 1 (ranging from 1.00 to 1.04). Conversely, all major depressive disorder odds ratio 
estimates were directionally consistent and ranged from 1.06 (95% CI: 0.81; 1.39) to 1.29 (95% CI: 1.01; 1.64).
Sensitivity analyses based on random effects meta-regression. Values of the meta-analytical meas-
ures of heterogeneity τ2 and I2 (not IGX
2 ) in the individual-SNP ratio estimates were 0.45 and 29.1% (P = 0.005) for 
bipolar disorder, 0.49 and 68.8% (P = 9.9 × 10−24) for schizophrenia, and 0.20 and 18.4% (P = 0.073) for major 
depressive disorder. In a random effects meta-regression model, including an indicator variable of influentiality 
status reduced τ2 and I2 values of major depressive disorder ratio estimates to 0.14 and 13.4%, respectively, with 
an adjusted-R2 value (which indicates the amount of heterogeneity explained by the moderators) of 29.3% 
(P = 0.028), and the test of residual between-instruments heterogeneity yielded P = 0.152. Regarding bipolar dis-
order and schizophrenia, the same procedure had a substantially smaller influence, with adjusted-R2 values of 
1.1% (P = 0.015; test of residual between-study heterogeneity P = 2.4 × 10−23) and 2.4% (P = 0.193; test of residual 
Characteristic Bipolar disorder Schizophrenia
Major depressive 
disordera
Number of cases/controls 7,481/9,250 34,241/45,604b 9,240/9,519
Number of BMI SNPs available 97 96 90
SNP-BMI F-statistic in GIANT
 Mean (standard deviation) 56.54 (75.98) 56.71 (76.36) 54.71 (77.02)
 Median (interquartile range) 34.98 (20.08) 34.72 (20.91) 33.34 (24.18)
SNP-BMI F-statistic in PGCc
 Mean (standard deviation) 3.01 (3.96) 14.35 (19.00) 3.36 (4.55)
 Median (interquartile range) 1.91 (1.25) 9.03 (5.82) 2.00 (1.39)
Overlap between GIANT and each PGC dataset
Number of SNPsd 2,421,360 2,480,664 1,093,724
Tetrachoric correlatione − 0.020 − 0.026 − 0.004
Table 1.  Characteristics of each psychiatric disorder dataset. BMI: Body mass index. GIANT: Genetic 
Investigation of Anthropometric Traits consortium. PGC: Psychiatric Genomics Consortium. aRefers to 62 
BMI-associated SNPs reported by the GIANT consortium and 28 proxies. bThis refers to the sample size from 
studies of unrelated individuals only. cThese are approximations based on the assumption that SNP-BMI 
associations are similar in cases and controls and between GIANT and PGC. dNumber of SNPs available and 
that had the same allele pair in both the GIANT and PGC. eComputed using truncated Z-statistics (1 if Z > 0 or 
0 if Z ≤ 0) of the SNP-phenotype associations (see Materials and Methods for details).
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between-study heterogeneity P = 0.006), respectively. When an indicator of belonging to a neuronal-related bio-
logical category was used instead of influentiality status, all adjusted-R2 values were 0%.
The results of the forward selection process of biological moderators of individual-SNP ratio estimates using 
random effects meta-regression are shown in Supplementary Table S1. Adopting a P ≥ 0.05 stopping criterion 
resulted in the selection of two moderators for each outcome: unspecified and endocytosis/exocytosis categories 
for bipolar disorder; neurotransmission and lipid-related for schizophrenia; and lipid-related and glucose home-
ostasis/diabetes for major depressive disorder. Adjusted-R2 and residual I2 values for the selected moderators 
together were 32.9% and 21.5% for bipolar disorder, 8.3% and 66.7% for schizophrenia and 68.8% and 6.5% for 
major depressive disorder. Mendelian randomization odds ratio estimates excluding each and both of the selected 
biological categories are shown in Supplementary Table S2. Again, only major depressive disorder presented 
directionally consistent estimates in all Mendelian randomization methods and SNP subgroups.
Discussion
In the present study, we evaluated the association between BMI-associated SNPs and three psychiatric disorders 
by Mendelian randomization using summary-level data. Only major depressive disorder presented consistent 
causal effect estimates using the three Mendelian randomization methods and in all sensitivity analyses. The fact 
that removing influential variants increased, rather than attenuated, the odds ratio estimates is also reassuring 
because it suggests that the true causal effect might be greater than that estimated using all variants simultane-
ously. However, the overall statistical evidence for any meaningful associations was weak.
Our findings suggest that the commonly positive association between obesity and psychiatric disorders 
reported in observational studies3–8 may not correspond to a causal risk-increasing effect (especially for bipolar 
disorder and schizophrenia). Such associations may have been driven by phenomena such as residual confound-
ing, due to common causes imperfectly accounted for at study design and/or analysis; or reverse causation, due to, 
for example, side effects of anti-psychotic medication. Even though associations of obesity with later depression 
and bipolar disorder have been reported in cohort studies3,12–14, it is still possible that reverse causation occurred 
Included SNPsa Parameter Statistic IVW
Weighted 
median MR-Egger MR-Egger (SIMEX)b
Outcome: Bipolar disorder
All Intercept Odds (95% CI) — — 0.99 (0.97; 1.01) 0.99 (0.97; 1.01)
(97 SNPs) P — — 0.281 0.294
OR OR (95% CI) 0.90 (0.69; 1.16) 0.88 (0.62; 1.25) 1.23 (0.65; 2.31) 1.26 (0.63; 2.52)
P 0.416 0.482 0.517 0.516
Non-influential Intercept Odds (95% CI) — — 0.99 (0.98; 1.01) 0.99 (0.98; 1.01)
(92 SNPs) P — — 0.319 0.335
OR OR (95% CI) 0.93 (0.74; 1.17) 0.88 (0.62; 1.26) 1.19 (0.69; 2.05) 1.21 (0.67; 2.20)
P 0.532 0.487 0.518 0.526
Outcome: Schizophrenia
All Intercept Odds (95% CI) — — 0.99 (0.98; 1.00) 0.99 (0.97; 1.00)
(96 SNPs) P — — 0.101 0.103
OR OR (95% CI) 0.98 (0.80; 1.19) 0.93 (0.78; 1.11) 1.41 (0.87; 2.27) 1.46 (0.86; 2.47)
P 0.806 0.420 0.162 0.161
Non-influential Intercept Odds (95% CI) — — 0.99 (0.98; 1.00) 0.99 (0.98; 1.01)
(92 SNPs) P — — 0.280 0.283
OR OR (95% CI) 1.01 (0.86; 1.18) 0.93 (0.78; 1.10) 1.22 (0.83; 1.81) 1.25 (0.81; 1.92)
P 0.944 0.406 0.310 0.315
Outcome: Major depressive disorder
All Intercept Odds (95% CI) — — 1.00 (0.98; 1.01) 1.00 (0.98; 1.01)
(90 SNPs) P — — 0.669 0.622
OR OR (95% CI) 1.15 (0.92; 1.44) 1.40 (1.03; 1.90) 1.28 (0.74; 2.24) 1.33 (0.72; 2.47)
P 0.221 0.035 0.374 0.364
Non-influential Intercept Odds (95% CI) — — 0.99 (0.98; 1.01) 0.99 (0.98; 1.01)
(86 SNPs) P — — 0.385 0.328
OR OR (95% CI) 1.25 (1.02; 1.52) 1.45 (1.05; 1.99) 1.52 (0.93; 2.49) 1.60 (0.93; 2.75)
P 0.030 0.026 0.094 0.087
Table 2.  Odds ratio (OR) estimates of bipolar disorder, major depressive disorder (MDD) and 
schizophrenia per 1-standard deviation increment in BMI based on IVW, MR-Egger and weighted median 
approaches. 95% CI: 95% Confidence interval. P: P-value. SIMEX: Simulation Extrapolation. aAll corresponds 
to Mendelian randomization analysis using all BMI-associated SNPs available in the correspondent psychiatric 
dataset. “Non-influential” is similar, but excludes SNPs classified as influential using statistical tests based on 
studentized residuals and Cook’s distance (see Materials and Methods for details). bThis differs from regular 
MR-Egger regression because it uses the SIMEX method to correct for regression dilution bias.
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due to effects (not related to medication usage) of pre-clinical psychiatric disorders on weight gain if such effects 
exist. Effects of pre-clinical psychiatric diseases have been recently detected in a longitudinal study where genetic 
predisposition to schizophrenia was associated with non-participation over time39.
Mendelian randomization studies on the association between obesity and psychiatric disorders are scarce, 
with no studies for bipolar disorders and schizophrenia. A positive association between BMI instrumented 
using the FTO variant rs1421085 and common mental disorders was detected in the British Whitehall II study25. 
Figure 2. SNP-BMI and SNP-psychiatric associations for up to 97 BMI-associated SNPs identified by 
the GIANT consortium. Influential SNPs were marked with an “X” and labelled using the correspondent 
gene locus. SNPs were classified as influential using statistical tests based on studentized residuals and Cook’s 
distance (see Materials and Methods for details). Left column: scatter plots of associations between SNPs and (a) 
bipolar disorder (b,d,c) schizophrenia and (e) major depressive disorder (MDD) against SNP-BMI associations. 
IVW, MR-Egger and weighted median estimates are indicated in solid, dashed and grey lines, respectively. Right 
column: funnel plots of the absolute value of the t-statistic of SNP-BMI association (ie, instrument strength) 
against individual-SNP ratio estimates in log odds ratio of (b) bipolar disorder, (d) major depressive disorder 
and (f) schizophrenia. IVW, MR-Egger and weighted median estimates are indicated in solid, dashed and grey 
lines, respectively.
www.nature.com/scientificreports/
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However, adiposity measures instrumented by FTO and MC4R variants were inversely associated with psycho-
logical distress in a much larger Danish cohort26. These findings must be interpreted cautiously since there is 
evidence that FTO27 and MC4R28 are pleiotropic, in accordance with suggestions that FTO might not be a valid 
instrument for BMI when mental disorders are the outcome25,29. In our study, the MC4R variant rs571312 (and 
others, but not FTO) was identified as an influential (and potentially invalid) instrument in major depressive 
disorder analysis, but not in the remaining outcomes. In the Young Finns cohort, BMI instrumented by a 31-SNP 
allele score was positively associated with depressive symptoms31. However, two other studies using a similar 
genetic instrument failed to detect any association with depression-related outcomes, with risk-decreasing point 
estimates29,32. Our study extends Mendelian randomization analysis of the causal effects of BMI on psychiatric 
outcomes by using the more recently described set of 97 BMI-associated variants.
Obesity and psychiatric disorders may share several dysregulated physiological pathways, including inflam-
mation40. Elevated inflammation is a potential cause of psychiatric disorders41 since positive associations between 
inflammatory markers and later psychiatric-related outcomes have been reported13,41. Given the well-defined 
role of obesity in inflammation, the later could be a mediator between obesity and psychiatric disorders. Indeed, 
a study among older English adults reported that C-reactive protein mediated about 20% of the longitudinal 
association between obesity and depressive symptoms13. However, there are only a few longitudinal studies 
evaluating this association41 and a large Mendelian randomization study did not suggest a causal association 
between C-reactive protein and depression42. The latter (assuming that higher BMI raises C-reactive protein 
levels) is in accordance with our inconsistent findings regarding the association of genetically elevated BMI with 
bipolar disorder and schizophrenia and the weak statistical evidence regarding the association with depression. 
Nevertheless, further studies are required to understand the role of inflammation and other biological pathways 




subgroup Statistic IVW Weighted median MR-Egger MR-Egger (SIMEX)e
Outcome: Bipolar disorder
Includeda Neuronalc OR (95% CI) 0.93 (0.66; 1.32) 0.89 (0.59; 1.34) 1.19 (0.54; 2.60) 1.19 (0.51; 2.75)
(54 SNPs) P 0.684 0.570 0.662 0.680
Otherd OR (95% CI) 0.83 (0.55; 1.27) 0.97 (0.57; 1.64) 1.33 (0.38; 4.68) 1.42 (0.32; 6.34)
(43 SNPs) P 0.386 0.902 0.645 0.636
Excludedb Neuronalc OR (95% CI) 0.94 (0.70; 1.27) 0.89 (0.59; 1.34) 1.09 (0.56; 2.10) 1.09 (0.54; 2.20)
(50 SNPs) P 0.698 0.574 0.802 0.809
Otherd OR (95% CI) 0.90 (0.62; 1.32) 0.97 (0.57; 1.66) 1.62 (0.52; 5.02) 1.81 (0.47; 6.97)
(42 SNPs) P 0.597 0.917 0.394 0.377
Outcome: Schizophrenia
Includeda Neuronalc OR (95% CI) 1.00 (0.80; 1.26) 0.93 (0.76; 1.13) 1.30 (0.77; 2.21) 1.33 (0.75; 2.34)
(54 SNPs) P 0.992 0.474 0.317 0.318
Otherd OR (95% CI) 0.93 (0.64; 1.35) 0.86 (0.66; 1.13) 1.75 (0.58; 5.24) 1.95 (0.53; 7.15)
(42 SNPs) P 0.687 0.285 0.311 0.306
Excludedb Neuronalc OR (95% CI) 1.06 (0.86; 1.30) 0.93 (0.76; 1.13) 1.15 (0.71; 1.86) 1.17 (0.70; 1.95)
(52 SNPs) P 0.602 0.472 0.554 0.545
Otherd OR (95% CI) 0.91 (0.70; 1.20) 0.86 (0.66; 1.12) 1.37 (0.61; 3.09) 1.46 (0.55; 3.88)
(40 SNPs) P 0.495 0.271 0.442 0.440
Outcome: Major depressive disorder
Includeda Neuronalc OR (95% CI) 1.16 (0.90; 1.50) 1.44 (1.01; 2.06) 1.26 (0.70; 2.27) 1.29 (0.69; 2.43)
(54 SNPs) P 0.254 0.051 0.424 0.422
Otherd OR (95% CI) 1.13 (0.71; 1.80) 1.36 (0.81; 2.28) 1.38 (0.28; 6.70) 1.52 (0.21; 10.83)
(36 SNPs) P 0.594 0.257 0.680 0.669
Excludedb Neuronalc OR (95% CI) 1.20 (0.94; 1.53) 1.48 (1.02; 2.15) 1.60 (0.92; 2.77) 1.66 (0.92; 3.00)
(52 SNPs) P 0.142 0.042 0.096 0.089
Otherd OR (95% CI) 1.37 (0.95; 1.98) 1.39 (0.82; 2.35) 1.46 (0.43; 4.97) 1.62 (0.36; 7.32)
(34 SNPs) P 0.090 0.227 0.536 0.517
Table 3.  Odds ratio (OR) estimates of bipolar disorder, major depressive disorder and schizophrenia 
per 1- standard deviation increment in BMI based on IVW, MR-Egger and weighted median approaches, 
within independent subgroups of SNPs defined using biological criteria. 95% CI: 95% Confidence interval. 
P: P-value. SIMEX: Simulation Extrapolation. aSNPs classified as influential using statistical tests based on 
studentized residuals and Cook’s distance (see Materials and Methods for details) were included. bSNPs 
classified as influential were excluded. cIncludes SNPs belonging to “neuronal developmental processes”, 
“neurotransmission”, “hypothalamic expression and regulatory function” or “neuronal Expression” biological 
categories. dIncludes SNPs belonging to the remaining biological categories. eThis differs from regular MR-Egger 
regression because it uses the SIMEX method to correct for regression dilution bias.
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European ancestry was predominant in all datasets, which increases the plausibility of the assumption that 
the two datasets are samples from the same or comparable populations. Regarding power, two-sample Mendelian 
randomization power depends more on the precision of SNP-outcome than SNP-exposure associations35. 
SNP-outcome associations used in this study were estimated in relatively small samples, except for schizophrenia. 
Sample size differences resulted in considerably different approximate SNP-BMI F-statistics across psychiatric 
datasets. Although SNP-BMI associations used in the analyses were obtained from GIANT, this difference sug-
gests that, for bipolar and major depressive disorders, SNP-outcome associations were too imprecise, which is 
likely to decrease power. Indeed, in spite of the consistency across Mendelian randomization methods and sensi-
tivity analyses, causal effect estimates for major depressive disorder – especially when using MR-Egger – had wide 
confidence intervals and in some cases failed to achieve conventional statistical significance levels. On the other 
hand, given the aforementioned consistency and the fact that sensitivity analyses suggested even stronger causal 
effect estimates, it is possible that there will be adequate statistical power to detect causal effects once more precise 
SNP-major depressive disorder estimates are available.
It is impossible to prove empirically whether Mendelian randomization results mostly reflect causal effects of 
the exposure or violations of instrumental variable assumptions. In the present study, three Mendelian random-
ization methods – each with different assumptions regarding horizontal pleiotropy – were used, and all of them 
were consistent regarding major depressive disorder, but not when analyzing bipolar disorder and shcizophrenia. 
Moreover, both MR-Egger regression and the weighted median approach (which are more robust against bias due 
to horizontal pleiotropy than IVW) point estimates were stronger than the IVW one. It was also reassuring that 
major depressive disorder presented the smallest heterogeneity in individual-SNP ratio estimates measured using 
the conventional I2 statistic, and that excluding four influential SNPs increased the magnitude of the causal effect 
estimates and further attenuated the I2 statistic.
In general, our findings do not corroborate the notion that BMI has a causal effect on bipolar disorder or 
schizophrenia. Regarding major depressive disorder, although the point estimates were consistent across a range 
of analyses, the overall statistical evidence was weak. Re-addressing this research question once SNP-depression 
associations from larger GWAS become available would be warranted to obtain more precise Mendelian rand-
omization estimates (especially with respect to MR-Egger regression). Given the high prevalence of both obesity 
and depression worldwide, understanding the mechanisms underlying associations between BMI and depression, 
with identification and quantification of causal effects, is of public health relevance. Analyses involving schizo-
phrenia were less prone to power issues because SNP-schizophrenia associations were estimated in a relatively 
large sample. Bipolar disorder, similarly to major depressive disorder, require further investigation once more 
precise SNP-outcome associations are available.
Materials and Methods
Data sources. The final datasets were provided in Supplementary Tables S3–S6.
Excluded biological category
Bipolar disorder Schizophrenia MDD
Number 
of SNPs OR (95% CI) P
Number 
of SNPs OR (95% CI) P
Number 
of SNPs OR (95% CI) P
Neuronal developmenta 68 0.88 (0.66; 1.18) 0.383 67 0.97 (0.77; 1.22) 0.792 61 1.13 (0.85; 1.51) 0.382
Neurotransmission 87 0.95 (0.72; 1.25) 0.718 86 1.04 (0.85; 1.28) 0.695 80 1.16 (0.91; 1.49) 0.228
Hypothalamus-relateda 84 0.75 (0.55; 1.03) 0.077 83 0.92 (0.71; 1.18) 0.484 77 1.07 (0.82; 1.41) 0.606
Neuronal expression 85 0.92 (0.70; 1.21) 0.552 84 0.99 (0.80; 1.22) 0.932 78 1.15 (0.90; 1.47) 0.250
Lipid-relateda 87 0.95 (0.73; 1.23) 0.674 86 1.04 (0.86; 1.26) 0.680 80 1.25 (1.00; 1.56) 0.051
Bone development 88 0.93 (0.71; 1.22) 0.588 87 0.97 (0.78; 1.20) 0.750 82 1.19 (0.94; 1.51) 0.149
MAPK1/Extracellular kinasesa 88 0.92 (0.71; 1.21) 0.559 87 0.97 (0.79; 1.19) 0.777 81 1.16 (0.92; 1.46) 0.217
Endocytosis/Exocytosis 83 0.98 (0.75; 1.28) 0.903 82 1.01 (0.81; 1.25) 0.963 76 1.12 (0.87; 1.44) 0.368
Tumorigenesis 86 0.92 (0.70; 1.20) 0.542 85 1.02 (0.82; 1.25) 0.885 79 1.16 (0.91; 1.48) 0.235
Apoptosis 84 0.92 (0.71; 1.21) 0.555 83 0.98 (0.79; 1.21) 0.837 78 1.23 (0.98; 1.54) 0.078
Membrane proteins 86 0.91 (0.68; 1.22) 0.534 85 0.98 (0.79; 1.23) 0.876 79 1.23 (0.96; 1.58) 0.097
Monogenic obesity/Energya 88 0.85 (0.63; 1.14) 0.271 87 0.94 (0.75; 1.18) 0.588 81 1.17 (0.90; 1.51) 0.229
Immune system 82 0.92 (0.70; 1.20) 0.527 81 0.98 (0.78; 1.22) 0.853 77 1.19 (0.93; 1.52) 0.165
Glucose homeostasis/diabetesa 86 0.90 (0.68; 1.19) 0.448 85 0.97 (0.78; 1.19) 0.743 79 1.29 (1.01; 1.64) 0.038
Cell cycle 74 0.95 (0.71; 1.26) 0.715 73 1.00 (0.79; 1.27) 0.985 70 1.06 (0.81; 1.39) 0.644
Unspecifieda 72 1.06 (0.81; 1.41) 0.655 72 1.03 (0.83; 1.28) 0.768 66 1.26 (0.97; 1.62) 0.081
Table 4.  Odds ratio (OR) estimates of bipolar disorder, major depressive disorder (MDD) and 
schizophrenia per 1- standard deviation increment in BMI based on the IVW approach, within subgroups 
of SNPs excluding one biological category at a time. 95% CI: 95% Confidence interval. P: P-value. aNeuronal 
development: Neuronal developmental processes. Hypothalamus-related: Hypothalamic expression and 
regulatory function. Lipid-related: Lipid biosynthesis and metabolism. MAPK1/Extracellular kinases: 
Mitogen activated protein kinase 1/Extracellular signal-regulated kinases. Monogenic obesity/Energy: 
Monogenic Obesity and/or Energy Homeostasis. Glucose homeostasis/diabetes: Glucose homeostasis and/or 
diabetes. Unspecified: Prioritized by GRAIL-Putative coding variant annotation-CNV-eQTL-DEPICT but not 
in above categories.
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Body mass index. Locke and colleagues’, under the GIANT consortium, identified 97 BMI-associated single 
nucleotide polymorphisms (SNPs)24. SNP-BMI linear regression coefficients and standard error estimates were 
obtained from an analysis of up to 322,154 European ancestry individuals assuming additive genetic effects 
(https://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files).
The outcome was obtained by applying an inverse normal transformation to BMI residuals on age and age2 
(in addition to relevant study-specific covariates such as ancestry-informative principal components). In studies 
of unrelated individuals, residuals were calculated within sex and (when relevant) case/control strata. In family 
studies, residuals were sex-adjusted rather than sex-specific.
To investigate the biological function of the 97 BMI-associated variants, Locke and colleagues assigned, for 
each SNP, all genes within 500 kb and r2 > 0.2. For variants without genes mapping to this interval, the nearest 
gene was used. This resulted in 405 genes, which were annotated based on a manual literature review using several 
venues. Through this process, those 405 genes were manually curated into 25 biological categories containing at 
least three genes, to which each of the 97 BMI-associated variants were assigned (see Locke and colleagues24 for 
details). We only considered the 16 categories that contained at least nine (~10%) SNPs (Supplementary Table 
5S). Those categories substantially overlapped: four of them (“neuronal developmental processes”, “neurotrans-
mission”, “hypothalamic expression and regulatory function” and “neuronal expression”) were neuronal-related 
and 62 SNPs were present in two or more categories. It is also noteworthy that those categories were aimed at 
providing insights into the biological processes implicated in obesity based on genetic associations rather than a 
detailed biological description of each SNP. Such biological categorizations are of approximate and provisional 
nature, changing over time as new data emerges43. The biological categories were used in the present work for 
sensitivity analyses purposes only (as described in the “Statistical analyses” section).
Psychiatric disorders. Log odds ratio and standard error estimates of SNPs-psychiatric disorders associations 
were obtained from the Psychiatric Genomics Consortium (PGC) (http://www.med.unc.edu/pgc/downloads), 
which performed logistic regression adjusting for ancestry-informative principal components and assuming an 
additive effect.
Bipolar disorder. Sklar and colleagues’ – under the PGC Bipolar Disorder Working Group – performed 
SNP-bipolar disorder associations on 7,481 cases and 9,250 controls of European descent44. All 97 BMI-associated 
SNPs were available. After harmonizing effect and non-effect alleles between SNP-bipolar disorder and SNP-BMI 
datasets, the Pearson correlation coefficient between effect allele frequencies was > 0.999.
Major depressive disorder. SNP-major depressive disorder associations correspond to the discovery stage anal-
ysis of Ripke and colleagues under the PGC Major Depressive Disorder Working Group in 9,240 cases and 9,519 
controls of European ancestry45.
Only 62 BMI-associated SNPs were available. Proxies for missing variants were identified using the SNP 
Annotation and Proxy Search tool (http://www.broadinstitute.org/mpg/snap/ldsearch.php). A proxy was defined 
as a genetic variant within 500 kb of the index SNP and in high linkage disequilibrium (r2 > 0.8) with it. If there 
was more than one proxy available for the same index SNP, the variant with the higher r2 was selected. Using 1000 
Genomes Pilot 1 (CEU population) as the reference panel, 26 proxies available in both SNP-BMI and SNP-major 
depressive disorder datasets were identified. An additional search using HapMap release 22 (CEU population) as 
the reference panel yielded two additional proxies, thus totalizing 28 proxy variants and 90 BMI-associated SNPs. 
After harmonization, the correlation between effect allele frequencies was 0.989.
Schizophrenia. Ripke and colleagues performed SNP-schizophrenia associations under the PGC Schizophrenia 
Working Group in 34,241 cases and 45,604 ancestry-matched controls (most of European ancestry), and three 
family-based studies comprising 1,235 parent affected-offspring European ancestry trios46. 96 BMI-associated 
SNPs were available (effect allele frequencies were unavailable).
Statistical analysis. In Mendelian randomization analyses, all BMI-associated SNPs available for each psy-
chiatric disorder were used (Table 1 and Supplementary Tables S3–S6). The following methods were used:
1. IVW method, consisting of a linear regression of SNP-outcome (dependent variable) on SNP-exposure 
coefficients (independent variable), weighting by the inverse of the squared SNP-outcome standard errors. 
The intercept is constrained at zero, which follows from the assumption that SNP-outcome associations are 
entirely mediated by the exposure35. This corresponds to a fixed effects meta-analysis of the ratio estimates 
from each genetic variant.
2. MR-Egger regression, which differs from the IVW method because the intercept is not constrained. This 
yields a causal effect estimate robust against horizontal pleiotropy under the InSIDE (Instrument Strength 
Independent on Direct Effect) assumption, which requires that the SNP-exposure and direct SNP-outcome 
associations are independent. The intercept provides a test for directional horizontal pleiotropy36.
Both IVW and MR-Egger regression (as currently implemented) make the so-called NOME (No 
Measurement Error) assumption. That is, they assume that the SNP-exposure (in this case BMI) association 
estimate is equal to the true association. NOME violations attenuate the causal effect estimate towards the null 
in two-sample MR studies, and MR-Egger regression has been shown to be more prone to such attenuation 
than IVW. Moreover, NOME violations might either inflate or attenuate the MR-Egger intercept (depending 
on presence of and directional consistency between the intercept and the causal effect estimate). A modified 
version of the I2 statistic – IGX
2  – has been proposed to quantify regression dilution in MR-Egger regression 
due to NOME violations, which can adjusted for using the SIMEX method38.
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3. Weighted median method, which provides a valid causal estimate if at least 50% of the weights (ie, the “infor-
mation” that each genetic instrument contributes to the estimate, which depends on the precision of individ-
ual estimates) come from valid instruments, regardless of whether or not horizontal pleiotropic effects of the 
remaining variants respect the InSIDE assumption37.
Point estimates and standard errors were calculated for the IVW, MR-Egger and weighted median meth-
ods using the code provided by Bowden et al.36,37. Since SNP-BMI associations were estimated using 
inverse-transformed BMI, the Mendelian randomization estimates can be interpreted as the odds ratio per 1-SD 
increment in BMI.
Sensitivity analyses. Sample overlap between GIANT and PGC datasets can bias causal effect estimates 
from Mendelian randomization towards the observational (and possibly confounded) estimate33,34. We evaluated 
the issue of sample overlap indirectly using a method developed for meta-analysis of dependent “omic” datasets47. 
Briefly, assuming that the null hypothesis is true for most of the genome, correlations between datasets regarding 
Z-statistics of the SNP-phenotype associations would be expected to be close to zero if there is no sample over-
lap. To improve robustness against “contamination” due to true signals (ie, common genetic effects), tetrachoric 
correlations for each pair of BMI-PGC datasets were computed using Z-statistics truncated into two categories: 
1 if Z > 0 or 0 if Z ≤ 0.
Mendelian randomization analyses were also performed within SNP subgroups of biological function: 
neuronal-related (comprising the “neuronal developmental processes”, “neurotransmission”, “hypothalamic 
expression and regulatory function” and “neuronal expression” categories); and non-neuronal (comprising the 
remaining categories). Consistency among different biological subgroups would argue against the role of hori-
zontal pleiotropy in the results.
To evaluate if the results were substantially driven by a few instruments, the analyses were repeated excluding 
influential SNPs. A SNP was classified as influential if at least one of two tests of influence (based on studentized 
residuals and Cook’s distance) yielded a P-value < 0.05. These were calculated separately for IVW or MR-Egger 
regression, but the same SNPs were classified as influential using either Mendelian randomization method. The 
null distributions of these tests were: Student’s t-distribution with degrees of freedom equal to the number of 
SNPs minus 2, for studentized residuals; or the F-statistic with joint degrees of freedom equal to (1, number of 
SNPs minus 1) (for IVW) or (1, number of SNPs minus 2) (for MR-Egger regression), for Cook’s distance48.
In exploratory analysis aimed at identifying factors associated with horizontal pleiotropy, individual-SNP 
ratio estimates (in this study, per-allele log odds of a psychiatric disorder divided by the correspondent per-allele 
change in inverse-transformed BMI residuals units) were used to calculate between-instrument heteroge-
neity, which corresponds to horizontal pleiotropy in the Mendelian randomization context49. Standard errors 
were obtained using the delta method50. Random effects meta-regression was used to evaluate how much of 
between-instrument heterogeneity (and, therefore, horizontal pleiotropy) can be explained by influentiality status 
and biological categories. For the latter, an additional analysis using a forward selection process was performed to 
identify categories that explain heterogeneity. Indicators of belonging to a given biological category were added 
one at a time based on the largest reduction in τ2, until no additional covariates reached P < 5%.
Two additional sensitivity analyses were performed: (i) IVW estimates within subgroups of SNPs exclud-
ing one biological category at a time; (ii) estimation of causal effects using the three Mendelian randomization 
methods after removing SNPs belonging to the biological categories identified in the forward selection process 
described above.
Analyses were performed using R 3.2.4 (www.r-project.org).
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